Properties
What is it?
International Nonproprietary Name - brimonidine Clinical-pharmacological group: Ophthalmology → Anti-glaucoma agents Composition 1 ml of the preparation contains: Active substance: brimonidine tartrate 2 mg. Excipients: benzalkonium chloride, boric acid, calcium chloride dihydrate, magnesium chloride hexahydrate, potassium chloride, sodium borate decahydrate, hypromellose, sodium chloride, sodium hydroxide and/or hydrochloric acid, water for injection. Pharmacotherapeutic group Sympathomimetics used for the treatment of glaucoma. Indications for use - Open-angle glaucoma; - Ocular hypertension (as monotherapy or in combination with other intraocular pressure-lowering drugs). Dosage and administration For topical use only. Instill one drop into the conjunctival sac of the affected eye 2 times a day, with an interval of approximately 12 hours between instillations. Contraindications - Hypersensitivity to brimonidine and other components of the preparation. - Concomitant therapy with monoamine oxidase inhibitors (MAO inhibitors) and tricyclic antidepressants; - Lactation period; - Children under 2 years of age. Effect on ability to drive and operate machinery Brimonidine may cause fatigue and/or drowsiness, blurred vision, and visual disturbances, especially in low light conditions. Therefore, it is necessary to avoid driving and hazardous activities during treatment. Use during pregnancy and lactation No teratogenic effects on the fetus were observed before clinical studies. However, it has been established that brimonidine crosses the placental barrier and is found in insignificant amounts in fetal blood serum. Controlled studies in pregnant women have not been conducted. The use of brimonidine during pregnancy is permissible only if the expected therapeutic effect for the mother outweighs the potential risk to the fetus. Animal studies have shown that brimonidine passes into breast milk. Breastfeeding should be discontinued during the use of the preparation. Use in pediatrics Rimonol is contraindicated in children under 2 years of age, as the safety of the preparation has not been studied in this age group. The use of the preparation is not recommended for children under 12 years of age.